Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
79 hedge funds and large institutions have $64.8M invested in Zynerba Pharmaceuticals, Inc in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 17 reducing their positions, and 20 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 17
6% less funds holding
Funds holding: 84 → 79 (-5)
18% less capital invested
Capital invested by funds: $79.1M → $64.8M (-$14.3M)
25% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 20
36% less call options, than puts
Call options by funds: $3.82M | Put options by funds: $5.95M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.07M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.82M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.28M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.26M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$599K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$4.4M |
| 2 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$2.33M |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$1.65M |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$486K |
| 5 |
LPL Financial
San Diego,
California
|
-$351K |
ZYNE Hedge Fund Activity: Q4 2019 in Review
79 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q4 2019, worth a combined $64.8M — down 18% from $79.1M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ZYNE and 15 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 29 added.
The largest buyer was Morgan Stanley, adding an estimated $2.07M. The largest seller was ETF Managers Group, cutting an estimated $4.4M.
- 79 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q4 2019, down from 84 in Q3 2019.
- Funds reported $64.8M of Zynerba Pharmaceuticals, Inc stock for Q4 2019, down 18% quarter-over-quarter.
- 15 funds opened new Zynerba Pharmaceuticals, Inc positions in Q4 2019 and 20 closed out, a net change of -5 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q4 2019 was Morgan Stanley, an estimated $2.07M added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q4 2019 was ETF Managers Group, an estimated $4.4M sold.
Based on aggregated 13F filings for Q4 2019.